8-K: Karyopharm Therapeutics Q2 2026: Myelofibrosis sNDA on Track, Endometrial Trial Misses

Karyopharm Therapeutics reported Q2 2026 results, with total revenue at $33.4 million, and reaffirmed full-year guidance, while advancing its myelofibrosis program towards an sNDA submission.

Summary

• Karyopharm Therapeutics announced its financial results for the second quarter ended June 30, 2026.
• Total revenue for the quarter was $33.4 million, with U.S. XPOVIO net product revenue at $30.8 million.
• The company reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million.
• The planned supplemental New Drug Application (sNDA) for selinexor in combination with ruxolitinib for myelofibrosis remains on track for an August 2026 submission under the Accelerated Approval pathway.
• The Phase 3 XPORT-EC-042 trial for endometrial cancer did not meet its primary endpoint of progression-free survival, though a trend favoring selinexor was observed.
• The company is actively evaluating financing opportunities and strategic alternatives to extend its cash runway and maximize stakeholder value.
• As of June 30, 2026, the company had $65.4 million in cash, cash equivalents, and investments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with significant progress on the myelofibrosis program offset by a missed endpoint in endometrial cancer and ongoing financial concerns.

Positives

• The planned sNDA submission for selinexor in combination with ruxolitinib for myelofibrosis is on track for August 2026, with potential for Priority Review.
• Phase 3 SENTRY trial data for myelofibrosis, presented at ASCO and EHA and published in the Journal of Clinical Oncology, showed promising results for spleen volume reduction and potential overall survival benefits.
• U.S. XPOVIO net product revenue increased to $30.8 million in Q2 2026 from $29.7 million in Q2 2025.
• Royalty revenue increased to $2.5 million in Q2 2026 from $1.6 million in Q2 2025, reflecting expanded global patient access.
• R&D and SG&A expenses decreased in Q2 2026 compared to Q2 2025 due to prioritization and cost containment efforts.
• Loss from operations improved to $22.5 million in Q2 2026 from $24.4 million in Q2 2025.

Negatives

• The Phase 3 XPORT-EC-042 trial for endometrial cancer did not meet its primary endpoint of progression-free survival.
• Total revenue decreased to $33.4 million in Q2 2026 from $37.9 million in Q2 2025.
• License and other revenue significantly decreased to $2.6 million in Q2 2026 from $8.2 million in Q2 2025, primarily due to the expiration of Menarini's R&D obligation.
• Interest expense increased to $13.1 million in Q2 2026 from $11.2 million in Q2 2025 due to higher outstanding debt and interest rates.
• Other expense, net, significantly increased to $32.1 million in Q2 2026 from $2.2 million in Q2 2025, largely due to fair value adjustments of embedded derivatives and warrants.
• Net loss widened to $67.0 million in Q2 2026 from $37.3 million in Q2 2025.
• The company expects its existing liquidity to fund current operating plans only into September 2026, with a significant debt payment due in September 2026 that could lead to a default if additional financing is not secured.

Risks

• Substantial doubt exists regarding Karyopharm's ability to continue as a going concern.
• The company's existing liquidity is expected to fund operating plans only into September 2026.
• A $15.8 million principal payment is due on the senior secured term loan facility on September 10, 2026, which could lead to an event of default if additional financing or a waiver is not obtained.
• The Phase 3 XPORT-EC-042 trial for endometrial cancer did not meet its primary endpoint, impacting future investment priorities.
• The commercial landscape for XPOVIO in multiple myeloma is increasingly competitive.
• There can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that its drug candidates will successfully complete clinical development or receive regulatory approval.
• The adoption of XPOVIO in the commercial marketplace and the timing and costs involved in commercialization are subject to uncertainty.
• Regulatory authorities, including the FDA, may require additional clinical trials or have different timing for decisions.

Future Outlook

Karyopharm reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million, including U.S. XPOVIO net product revenue guidance of $115 million to $130 million. R&D and SG&A expenses are expected to be between $230 million and $245 million, excluding certain one-time costs. The company expects its current liquidity to fund operating plans into September 2026 and is actively evaluating financing opportunities and strategic alternatives.

Management Comments

• "Our planned submission under the Accelerated Approval pathway represents the beginning of an important new chapter for Karyopharm and an important milestone for the myelofibrosis community," said Richard Paulson, President and Chief Executive Officer of Karyopharm.
• "If approved, selinexor plus ruxolitinib would become the first approved combination therapy for patients with myelofibrosis, introducing a novel therapeutic mechanism for the treatment of this disease within the multi-billion-dollar U.S. marketplace."
• "We look forward to continuing to work closely with the FDA."
• "Together with the continued scientific engagement we are seeing across the myelofibrosis community, we believe the strength and consistency of the SENTRY data reinforce the potential of selinexor to fundamentally change the treatment of patients with myelofibrosis," added Mr. Paulson.

Industry Context

StockSavvy.ai notes that Karyopharm's progress in myelofibrosis aligns with the industry trend of seeking combination therapies and novel mechanisms for challenging hematological malignancies. However, the failure to meet the primary endpoint in the endometrial cancer trial highlights the inherent risks and variability in drug development, even for drugs with established mechanisms.

Comparison to Industry Standards

• The myelofibrosis market is a multi-billion dollar U.S. marketplace, with JAK inhibitors like ruxolitinib being the only approved class of therapies.
• The development of selinexor plus ruxolitinib as a potential first-in-class combination therapy for myelofibrosis aims to address a significant unmet need.
• In endometrial cancer, the trial results for selinexor as maintenance therapy did not meet the primary endpoint, which is a common challenge in oncology trials, particularly when targeting specific patient populations like TP53 wild-type.
• Competitors in the multiple myeloma space are also advancing all-oral combinations, making commercial success dependent on differentiation and efficacy.

Stakeholder Impact

• Shareholders: The missed endpoint in endometrial cancer and the precarious financial situation may negatively impact shareholder value, while progress in myelofibrosis offers potential upside.
• Creditors: The company's liquidity concerns and upcoming debt payment pose a risk to lenders if financing is not secured.
• Employees: Uncertainty regarding the company's financial runway and strategic alternatives could impact employee morale and job security.
• Patients: The potential approval of selinexor plus ruxolitinib offers a new therapeutic option for myelofibrosis patients, while the endometrial cancer trial outcome may limit options for that patient group.

Next Steps

• Submit sNDA for selinexor in combination with ruxolitinib for myelofibrosis in August 2026.
• Request Priority Review for the myelofibrosis sNDA.
• Advance global regulatory activities with partners for potential ex-U.S. submissions.
• Potentially include selinexor plus ruxolitinib in relevant compendia in H2 2026.
• Report topline data from the Phase 2 SENTRY-2 60 mg cohort in H2 2026.
• Maintain commercial foundation and drive XPOVIO revenues in multiple myeloma.
• Support global launches by partners for selinexor in ex-U.S. countries.
• Announce topline data from the Phase 3 XPORT-MM-031 (EMN29) trial in H2 2026.

Key Dates

Recommendation

The company shows promising progress in its myelofibrosis program, which could be a significant value driver. However, the failure to meet the primary endpoint in the endometrial cancer trial, coupled with significant financial concerns and the need for additional financing to continue operations, introduces substantial risk. A 'hold' recommendation reflects the balance between potential upside from the myelofibrosis indication and the considerable near-term risks.

Keywords

myelofibrosis, selinexor, XPOVIO, Karyopharm Therapeutics, sNDA submission, Phase 3 trial, financial results, cancer therapy